Biotech Values

[genisi]

I don't think the 0.5ml formulation (indeed it has the same active ingredient) has something that is patentable, it is quite obvious that a lower vol (less sterile water and mannitol) should cause less injection site pain. Teva clearly hopes to delay a generic to the 1ml product. Teva has another formulation - 40mg dose/three times a week for the same purpose.